Stockscreener 앱 받기
1.03
2.83%
-0.03
전일 마감가:
$1.06
열려 있는:
$1.09
하루 거래량:
176.44K
Relative Volume:
0.12
시가총액:
$27.08M
수익:
$1.79M
순이익/손실:
$-70.90M
주가수익비율:
-0.0663
EPS:
-15.54
순현금흐름:
$-34.95M
1주 성능:
-7.21%
1개월 성능:
-17.60%
6개월 성능:
-47.72%
1년 성능:
-75.42%
1일 변동 폭
$1.03
$1.09
1주일 범위
$1.03
$1.13
52주 변동 폭
$1.03
$5.10
센티 바이오사이언시스 Stock (SNTI) Company Profile
명칭
Senti Biosciences Inc
전화
(650) 239-2030
주소
2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO
SNTI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SNTI
Senti Biosciences Inc
|
1.03 | 27.87M | 1.79M | -70.90M | -34.95M | -15.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
센티 바이오사이언시스 Stock (SNTI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-14 | 개시 | H.C. Wainwright | Buy |
| 2025-06-06 | 개시 | Laidlaw | Buy |
| 2022-10-07 | 개시 | Morgan Stanley | Equal-Weight |
센티 바이오사이언시스 주식(SNTI)의 최신 뉴스
Block Trades: Is Senti Biosciences Inc benefiting from innovation trendsInflation Watch & Technical Pattern Recognition Alerts - baoquankhu1.vn
Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company's Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation - marketscreener.com
Profit Recap: What are the analyst revisions for Senti Biosciences IncIs ICON stock a good investment in YEARTake Profit & Accurate Entry/Exit Alerts - baoquankhu1.vn
Senti Biosciences, Inc. Highlights FDA RMAT Designation for SENTI-202 in Virtual Investor CEO Connect Segment - Quiver Quantitative
Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company’s Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation - marketscreener.com
FDA RMAT status and early leukemia data put Senti Bio therapy in focus - Stock Titan
Published on: 2026-01-14 09:14:03 - Bộ Nội Vụ
Breakouts Watch: Should I hold or sell Senti Biosciences Inc stock in 2025 - Bộ Nội Vụ
Senti Biosciences, Inc. (NASDAQ:SNTI) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Senti Bio to Participate in Panel Presentation at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference - The Manila Times
SNTI Stock Price, Forecast & Analysis | SENTI BIOSCIENCES INC (NASDAQ:SNTI) - Chartmill
Trading Action: Why Senti Biosciences Inc. stock is a value investor pickJuly 2025 Market Mood & Reliable Breakout Stock Forecasts - ulpravda.ru
Quarterly Recap: Can Senti Biosciences Inc. stock beat market expectations this quarterPortfolio Value Summary & Smart Money Movement Tracker - ulpravda.ru
Will Senti Biosciences Inc. stock outperform value stocksRisk Management & AI Forecasted Stock Moves - Улправда
Why Senti Biosciences Inc. stock is a value investor pick2025 Sector Review & Free Daily Entry Point Trade Alerts - Улправда
Why Senti Biosciences Inc. stock remains on buy listsM&A Rumor & Growth Focused Investment Plans - Улправда
Why Senti Biosciences Inc. stock is rated strong buyMarket Sentiment Review & Entry Point Strategy Guides - Улправда
Stock Market Recap: Is Senti Biosciences Inc. stock a good choice for value investorsEarnings Summary Report & Fast Gaining Stock Strategy Reports - ulpravda.ru
Can Senti Biosciences Inc. stock beat market expectations this quarterTrade Analysis Report & Weekly Watchlist of Top Performers - Улправда
Senti Biosciences Inc. (SNTI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Promising Biotech Stocks To Keep An Eye OnDecember 9th - MarketBeat
Guidance Update: Is Senti Biosciences Inc stock a good choice for value investorsAnalyst Downgrade & Free Verified High Yield Trade Plans - moha.gov.vn
Senti Biosciences, Inc. (SNTI) Stock: Faces Decline Despite Groundbreaking FDA Designation - parameter.io
How sustainable is Senti Biosciences Inc. stock dividend payoutEarnings Miss & High Yield Equity Trading Tips - Улправда
Comparing Longeveron (NASDAQ:LGVN) & Senti Biosciences (NASDAQ:SNTI) - Defense World
Will Senti Biosciences Inc. stock deliver strong dividend growthChart Signals & Growth Focused Stock Pick Reports - ulpravda.ru
Is Senti Biosciences Inc. stock a good choice for value investors2025 Macro Impact & Weekly High Return Stock Forecasts - Bölüm Sonu Canavarı
Income Plays: How institutional buying supports Senti Biosciences Inc. stock2025 Earnings Impact & Real-Time Volume Analysis - Улправда
Why retail investors pile into Senti Biosciences Inc. stock2025 Sector Review & Real-Time Volume Triggers - DonanımHaber
Senti Biosciences Announces New Employment Inducement Grants - The Manila Times
Does Senti Biosciences Inc. stock trade at a discount to peersMarket Movement Recap & Safe Capital Growth Plans - Улправда
New Senti Biosciences hire receives stock options in equity plan - Stock Titan
Senti Biosciences, Inc. (NASDAQ:SNTI) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Senti Biosciences Earnings Notes - Trefis
Senti Biosciences (NASDAQ:SNTI) Rating Increased to Sell at Wall Street Zen - Defense World
Promising Biotech Stocks To Keep An Eye On – December 9th - Defense World
Senti Bio Wins FDA RMAT Designation for SENTI-202 on 50% Response Rate in Leukemia Trial - geneonline.com
Senti Biosciences: Understanding the Market Moves - StocksToTrade
Chardan Raises Price Target on Senti Biosciences to $13 From $12, Keeps Buy Rating - marketscreener.com
Check Out Senti Biosciences Inc (SNTI)’s Trade Data Rather Than the Analysts’ Views - Setenews
Senti Bio’s SENTI-202 shows promising results in AML clinical trial By Investing.com - Investing.com Australia
Biotech Stocks Today: FDA Shifts, ASH 2025 Winners and Market Close Recap (December 9, 2025) - ts2.tech
Unveiling Senti Biosciences: Shaping the Future of Cancer Therapy? - StocksToTrade
Senti Bio price target raised to $13 from $12 at Chardan - TipRanks
Why Is Gene Therapy Focused Senti Bio Stock Falling Today? - Benzinga
SNTI: SENTI-202 achieved 50% ORR and 42% CR/CRh with deep, durable remissions in R/R AML - TradingView — Track All Markets
Lyft Stock Soars Following Strategic Euro Expansion Through FreeNow Acquisition - StocksToTrade
“Smart” NK Cells: Senti Bio’s Logic-Gated Immunotherapy Strikes R/R AML - Inside Precision Medicine
Senti Biosciences’ Strategic Moves Ripple Across Biotech Market - timothysykes.com
Senti Biosciences Secures FDA RMAT Designation For SENTI-202 - Nasdaq
센티 바이오사이언시스 (SNTI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
센티 바이오사이언시스 주식 (SNTI) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Lu Timothy K | CEO |
Feb 06 '25 |
Sale |
4.36 |
545 |
2,376 |
82,082 |
| Rajangam Kanya | Pres. & Chief Med. & Dev. Off. |
Feb 04 '25 |
Sale |
4.07 |
1,297 |
5,279 |
8,803 |
| Rajangam Kanya | Pres. & Chief Med. & Dev. Off. |
Feb 06 '25 |
Sale |
4.37 |
182 |
795 |
8,621 |
4.73%
0.92%
자본화:
|
볼륨(24시간):